Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
31 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
NeGIO Therapeutics from Charleroi, company number BE0799822012, closed financial year 2025 with a result of € -607,875 after tax. For that financial year NeGIO Therapeutics recorded a gross margin of € -196,240 and equity of € 4.8 million. Compared with financial year 2024, the result moved from € -2.7 million to € -607,875. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 26, 2026.
€ 4.8 million
▼ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -607,875
▲ 77 % less loss than in 2024
Profit after tax over the fiscal year.
€ 4.4 million
▲ 171% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -5.3 million.
People and assets in 2025
1.5
▼ 5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 335,245
▼ 48% vs 2024
€ 223,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 12,356
▼ 95% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € -1,726,793 | € -2,056,776 | € -196,240 | ▲ € 1.9 million |
| Profit after taxes | € -2,062,572 | € -2,663,400 | € -607,875 | ▲ € 2.1 million |
| Equity | € 8,022,412 | € 5,359,012 | € 4,751,137 | ▼ 11% |
| Total debts | € 376,029 | € 340,018 | € 12,356 | ▼ 96% |
| Cash | € 6,697,355 | € 1,614,863 | € 4,370,676 | ▲ 171% |
| Retained profit | € -2,062,572 | € -4,725,972 | € -5,333,847 | ▼ € 607,875 |
| Balance sheet total | € 8,398,442 | € 5,699,030 | € 4,763,493 | ▼ 16% |
| Employees (FTE) | 2.6 | 6.5 | 1.5 | ▼ 5 |
Key figures of NeGIO Therapeutics, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NeGIO Therapeutics?
What happened at NeGIO Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- AdBio Partners SAS stepped down as director. NBB
- Jan Van den Bossche stepped down as director. NBB
- Vives Partners SRL stepped down as director. NBB
- Thierry Hercend stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 607,875. Source: NBB ↗
- AdBio Partners SAS became a director. NBB
- Vives Partners SRL became a director. NBB
- New establishment in Sint-Lambrechts-Woluwe. KBO
In short
From € 2.1 million loss in 2023 to € 607,875 loss in 2025.
Paid € 912 in corporate taxes since 2023.
Management
The stake of Vives Inter-University Fund, SOPARTEC, INVESTSUD TECH, B2START comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
NeGIO TherapeuticsThe shares are held by Vives Inter-University Fund (12.6%), SOPARTEC (8.7%), INVESTSUD TECH (1.1%) and B2START (1.1%).
Directors
According to the 2025 annual accounts
Director · represented by Alain Huriez
since 2025 · until 2029
Jan Van den Bossche
Director
since 2023 · until 2029
Director · represented by Philippe Durieux
Also active at: NOVADIP BIOSCIENCES, TESSARES, AXINESIS, Sunrise, ViroVet, The Akkermansia Company, VOCSens, Vives Inter-University Fund +4 more
since 2024 · until 2029
Thierry Hercend
Director
since 2023 · until 2029
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Hippokrateslaan 75
1200 Sint-Lambrechts-Woluwe
Active since 3 July 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
All companies at this address →Brussels South Charleroi BioPark Dev
€ 80,186 gross margin · 2025
ImmunXperts
€ 393,338 gross margin · 2024
LYS MEDICAL
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
+26 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0799.822.012
- VAT number
- BE 0799.822.012
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- NeGIO Therapeutics · NeGIO
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 March 2023
- Peppol
- Active · Active since 31 Dec 2025
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen